Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience

Lignende værker

• Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules
  af: Atkinson, Bradley J., et al.
  Udgivet: (2013)
• Timing of mTORI usage and outcomes in kidney transplant recipients
  af: Lim, Lee-Moay, et al.
  Udgivet: (2021)
• Outcomes of Patients with Metastatic Clear-cell Renal Cell Carcinoma Treated with Second-Line VEGFR-TKI after First-Line Immune Checkpoint Inhibitors
  af: Shah, AY, et al.
  Udgivet: (2019)
• Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor‐Tyrosine Kinase Inhibitor Therapies
  af: Wiele, Andrew J., et al.
  Udgivet: (2021)
• Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after progression during treatment with other targeted therapies
  af: Matrana, M. R., et al.
  Udgivet: (2013)